omniture
EIRGENIX INC.

Latest News

EirGenix's Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives

TAIPEI, May 8, 2023 /PRNewswire/ -- EirGenix, Inc. (6589.TT) announced on 28th of April that it has...

2023-05-08 10:00 1992

Positive Phase III Clinical Results for EirGenix's Proposed Trastuzumab Biosimilar

TAIPEI, March 24, 2021 /PRNewswire/ -- In a press conference today, EirGenix, Inc. (6589.TT) announ...

2021-03-24 23:27 2828

Eirgenix Receives Approval from Japan's PMDA

TAIPEI, Feb. 14, 2020 /PRNewswire/ -- EirGenix, Inc. (6589, TT) had undertaken the transfer of drug...

2020-02-14 15:14 2319

EirGenix, Inc. Enters Into Global License Agreement for the Commercialization of its Biosimilar Drug EG12014

NEW TAIPEI CITY, , April 30, 2019 /PRNewswire/ -- EirGenix, Inc. announced today that it has entere...

2019-04-30 08:20 2658